3 points, SCA Band 2, 0.0625 EFTSL
Postgraduate - Unit
Refer to the specific census and withdrawal dates for the semester(s) in which this unit is offered.
Faculty
Pharmacy and Pharmaceutical Sciences
Coordinator(s)
Quota applies
This unit is quota restricted. Selection is on a first-in, first enrolled basis. For more information please contact the faculty at http://www.monash.edu.au/pharm/future/contact/
Unit guides
Notes
- Previously coded PGW1109
- For postgraduate coursework pharmacy discontinuation dates, please see http://www.pharm.monash.edu.au/students/pg-coursework/unit-discontinuation-dates.html
Synopsis
This unit discusses the more common causes of cutaneous ulceration other than venous insufficiency i.e. skin cancer. The three main types of skin cancer are described, as are the principles of treatment and prognosis Other topics covered include clinical features and treatment of Eczema, Vasculitis, Necrobiosis lipoidica, Pyoderma gangrenosum, Mycobacterium Ulcerans and Chromoblastomyosis.
Outcomes
At the completion of this unit students will be able to:
- Discuss the common causes of cutaneous ulcers.
- Discuss the diagnosis and treatment of skin cancers.
- Demonstrate an understanding of the diagnosis and management of dermatitis (eczema).
- Demonstrate an understanding of the diagnosis and management of less common cause of cutaneous ulcers.
Assessment
Minor assignment: 30%
Major written assignment: 60% (hurdle)
Participation in online tutorials: 10%
Workload requirements
Minimum total expected workload to achieve the learning outcomes for this unit is 72 hours per semester typically comprising a mixture of scheduled learning activities and independent study. The unit requires on average 5-6 hours of scheduled activities per week. Scheduled activities may include teacher directed learning, reading time, participation in tutorials or discussion groups, research and preparation for assignments.
See also Unit timetable information
Chief examiner(s)
This unit applies to the following area(s) of study
Prohibitions
PGW1109 (VCW1109)